Results 31 to 40 of about 13,549 (163)

Pulmonary arterial hypertension associated with carfilzomib

, 2021
To assess the association between carfilzomib and pulmonary arterial hypertension in the WHO pharmacovigilance ...
Charles Khouri
core   +1 more source

Carfilzomib: a novel agent for multiple myeloma [PDF]

, 2013
Objectives Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma ( MM ). This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and ...
Redic, Kimberly
core   +1 more source

Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy

Biomedicines, 2022
Background: Carfilzomib, the proteasome inhibitor, can increase the overall survival rate of multiple myeloma (MM) patients undergoing targeted therapy.
Chin-Mu Hsu, Chia-Hung Yen, Shu-Chen Wang, Yi-Chang Liu, Chien-Tzu Huang, Min-Hong Wang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yuh-Ching Gau, Jeng-Shiun Du, Hui-Ching Wang, Shih-Feng Cho, Yuhsin Tsai, Chi-En Hsiao, Samuel Yien Hsiao, Hui-Hua Hsiao   +16 more
doaj   +1 more source

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma

Journal of Hematology & Oncology, 2016
Purpose The purpose of this study was to better understand the efficacy and safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma(R/RMM). Methods We retrieved and reviewed published reports
Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng, Lida Wang   +4 more
doaj   +1 more source

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database

eJHaem, 2022
Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a ...
Arleigh McCurdy, Martha Louzada, Christopher P. Venner, Alissa Visram, Esther Masih‐Khan, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Richard LeBlanc, Michael Sebag, Kevin Song, Darrell White, Hira Mian, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece   +17 more
doaj   +1 more source

Mineralocorticoid Receptor signaling emerges as a key mediator of Carfilzomib induced increase in blood pressure. Prophylactic potential of Eplerenone.

, 2023
Introduction: Carfilzomib (Carfilzomib), is a first-line irreversible proteasome inhibitor indicated for relapsed/refractory multiple myeloma, presenting life-threatening cardiovascular adverse effects.
Makridakis, M (via Mendeley Data), Makridakis, Manousos   +1 more
core   +1 more source

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR [PDF]

, 2021
To understand the profile of best responders (complete response or better [≥CR]) to carfilzomib, we described the characteristics, progression-free survival (PFS), overall survival (OS) data, and the safety of patients who achieved ≥CR to carfilzomib ...
Weisel, Katja, Gay, F., Gay, F, Moreau, Philippe, Szabo, Z, Desgraz, R, Mateos, Maria Victoria, Gay, Francesca, Delforge, Michel, Desgraz, Renaud, Cook, G, DeCosta, Lucy, DeCosta, L, Szabo, Zsolt, Moreau, P, Weisel, Katja C., Mateos, Maria-Victoria, Mateos, M-V, Delforge, M, Cook, Gordon, Weisel, K   +20 more
core   +1 more source

Carfilzomib potentiates platelet activation and thrombus growth

, 2022
Background: Multiple Myeloma (MM) patients treated with carfilzomib are at high risk of venous thromboembolism (VTE), however, the underlying aetiology and mechanism remains unknown.
Fahd Kuriri (20065404), Denise Jackson (18031252), Kate Burbury (13532056), Fehaid Mazyad A Alanazi (20064210), Faith Kwa (20083317), Ezeldine Abdalhabib (20077959), Gasim Dobie (17391264), Isaac Goncalves (20083314)   +7 more
core  

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

Haematologica, 2021
The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results.
Kwee L. Yong, Samantha Hinsley, Holger W. Auner, Ceri Bygrave, Martin F. Kaiser, Karthik Ramasamy, Ruth M. de Tute, Debbie Sherratt, Louise Flanagan, Mamta Garg, Stephen Hawkins, Catherine Williams, Jamie Cavenagh, Neil K. Rabin, James Croft, Gareth Morgan, Faith Davies, Roger G. Owen, Sarah R. Brown   +18 more
doaj   +1 more source

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy [PDF]

, 2019
Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy. Carfilzomib, a second‐generation proteosomal inhibitor, results in a lower incidence of neuropathy than bortezomib, but data in AL is
Sharpley, F, Popat, R, Shah, R, Lachmann, HJ, Gillmore, JD, Kyriakou, C, Hawkins, PN, Mahmood, S, Cheesman, S, Manwani, R, Rabin, N, Worthington, S, Yong, K, Sachchithanantham, S, Wechalekar, AD, Smith, M   +15 more
core   +2 more sources